These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 21761401)

  • 1. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
    Kojima K; Duvvuri S; Ruvolo V; Samaniego F; Younes A; Andreeff M
    Cancer; 2012 Feb; 118(4):1023-31. PubMed ID: 21761401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
    Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
    Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
    Vogler M; Butterworth M; Majid A; Walewska RJ; Sun XM; Dyer MJ; Cohen GM
    Blood; 2009 Apr; 113(18):4403-13. PubMed ID: 19008458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
    van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
    Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
    Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
    Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
    Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z
    Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
    Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
    Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Davids MS; Hallek M; Wierda W; Roberts AW; Stilgenbauer S; Jones JA; Gerecitano JF; Kim SY; Potluri J; Busman T; Best A; Verdugo ME; Cerri E; Desai M; Hillmen P; Seymour JF
    Clin Cancer Res; 2018 Sep; 24(18):4371-4379. PubMed ID: 29895707
    [No Abstract]   [Full Text] [Related]  

  • 11. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.
    Al-Harbi S; Hill BT; Mazumder S; Singh K; Devecchio J; Choudhary G; Rybicki LA; Kalaycio M; Maciejewski JP; Houghton JA; Almasan A
    Blood; 2011 Sep; 118(13):3579-90. PubMed ID: 21772052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis.
    Pujals A; Renouf B; Robert A; Chelouah S; Hollville E; Wiels J
    Cell Death Dis; 2011 Jul; 2(7):e184. PubMed ID: 21796156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.
    Vogler M; Dinsdale D; Sun XM; Young KW; Butterworth M; Nicotera P; Dyer MJ; Cohen GM
    Cell Death Differ; 2008 May; 15(5):820-30. PubMed ID: 18309326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.
    Bates DJ; Danilov AV; Lowrey CH; Eastman A
    Mol Cancer Ther; 2013 Aug; 12(8):1504-14. PubMed ID: 23723123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
    Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
    Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells.
    Klymenko T; Brandenburg M; Morrow C; Dive C; Makin G
    Mol Cancer Ther; 2011 Dec; 10(12):2373-83. PubMed ID: 22006676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.
    Del Gaizo Moore V; Brown JR; Certo M; Love TM; Novina CD; Letai A
    J Clin Invest; 2007 Jan; 117(1):112-21. PubMed ID: 17200714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.
    Tsao T; Shi Y; Kornblau S; Lu H; Konoplev S; Antony A; Ruvolo V; Qiu YH; Zhang N; Coombes KR; Andreeff M; Kojima K; Konopleva M
    Ann Hematol; 2012 Dec; 91(12):1861-70. PubMed ID: 22893484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
    Mason KD; Khaw SL; Rayeroux KC; Chew E; Lee EF; Fairlie WD; Grigg AP; Seymour JF; Szer J; Huang DC; Roberts AW
    Leukemia; 2009 Nov; 23(11):2034-41. PubMed ID: 19641525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABT-737, proving to be a great tool even before it is proven in the clinic.
    Vaux DL
    Cell Death Differ; 2008 May; 15(5):807-8. PubMed ID: 18408737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.